Skip to main content
. 2012 May 9;109(21):8173–8178. doi: 10.1073/pnas.1205848109

Fig. 5.

Fig. 5.

Deletion of Shn3 in Prx1-expressing cells leads to a high bone mass phenotype with decreased bone catabolism in vivo. (A) Representative metaphyseal (Left) and midshaft (Right) microcomputed tomography (micro-CT) images of mice of the indicated genotype. (B–D) Micro-CT–derived metaphyseal BV/TV, trabecular number (Tb.N), and trabecular thickness (Tb.Th) of mice of the indicated genotype. (E) Micro-CT–derived diaphyseal (midshaft) BV/TV (M.BV/TV) of mice of the indicated genotype. Osteoblastic parameters in vivo are provided as determined by dynamic (F) and static histomorphometry (H), as well as serum P1NP levels (G). BFR/BS, bone formation rate/bone surface; Ob.S/BS, osteoblast surface/bone surface. Osteoclastic parameters in vivo are determined by static histomorphometry (I) and serum CTX levels (J). Oc.S/BS, octeoclast surface/bone surface. Comparison of Prx1-Cre transgene-negative and -positive animals for all parameters shown. P < 0.05.